Nicholas Reville, co-founder of the Center for Addiction Science, discusses innovative approaches to combat addiction. He explores how GLP-1 weight loss drugs, initially for diabetes, may help curb cravings for substances like alcohol and opioids. Reville emphasizes the urgent need for new treatments amid the opioid crisis and examines Big Pharma's troubled history in addiction management. He calls for collaborative efforts and effective frameworks to advance addiction research and improve treatment outcomes.

Nicholas Reville, Director of CASPR and an expert in addiction medicine, discusses the promising use of GLP-1 drugs like Ozempic in combating addiction. He argues for wider access to these medications, highlighting their potential to mitigate cravings linked to substance use disorders. The conversation touches on the off-label use of these drugs, the importance of ongoing research, and the role of compounding pharmacies in improving accessibility. Reville also calls for policy changes to encourage more pharmaceutical investment in addiction treatments, likening it to the impact of Narcan.